scholarly journals P1-199: Aberrant methylation of p16 tumor suppressor gene and retinoic acid receptor b2 in malingnant pleural effusion

2007 ◽  
Vol 2 (8) ◽  
pp. S816
Author(s):  
Choonhee Son ◽  
Seo-Hee Rha ◽  
Dookyung Yang ◽  
Sookeol Lee ◽  
Ki-Nam Lee ◽  
...  
2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 469-469
Author(s):  
Yanxin Luo ◽  
Andrew Kaz ◽  
Samornmas Kanngurn ◽  
William M. Grady

469 Background: Neurotrophin tyrosine kinase receptor 3 (NTRK3) is a receptor tyrosine kinase that has been shown to be an oncogene in breast cancer and possibly in hepatocellular carcinoma. NTRK3 is a trophic dependence receptor, which is a recently described class of receptors that initiate signaling in both the ligand bound and unbound states. Through a genome-wide screen for aberrantly methylated genes, we identified aberrantly methylated NTRK3 as a frequently methylated gene in colon cancer. The aim for the present study is to determine if NTRK3 is an epigenetically silenced tumor suppressor gene in colorectal cancer. Methods: NTRK3 promoter methylation was analyzed in human colon cancer cell lines, normal colon epithelium tissue, colorectal adenomas and colorectal cancers using quantitative methylation-specific PCR and bisulfite sequencing. NTRK3 mRNA and protein expression were studied using quantitative real-time PCR, immunohistochemistry and western blotting respectively. The tumor suppressor function of NTRK3 was examined by assessing the effect of NTRK3 on cell apoptosis, cell migration and in vitro colony formation assays in colon cancer cell lines stably transfected with an NTRK3 expression construct in the presence or absence of NT-3. Results: NTRK3 is methylated in 60% of colon adenomas and in 57% of colorectal cancers. The aberrant methylation of NTRK3 suppresses NTRK3 expression and releases colon cancer cells from NTRK3 mediated apoptosis induced by the expression of NTRK3 in the absence of the ligand NT-3 via the activation of MAPK/ERK pathway. Methylation of NTRK3 also releases colon cancer cells from NTRK3 mediated suppression of motility and anchorage independent growth. The addition of NT3 to colon cancer cells transfected with NTRK3 inhibits the tumor suppressor effects of NTRK3. Conclusions: The aberrant methylation of NTRK3 is likely functionally relevant for colorectal cancer formation as NTRK3 appears to be a conditional tumor suppressor gene in the colon depending on the expression status of its ligand NT-3. NTRK3 is a novel aberrantly methylated conditional tumor suppressor gene that is frequently methylated in colon adenomas and cancers and whose discovery reveals possible novel treatment approaches to colon cancer.


2020 ◽  
Author(s):  
Ben Xu ◽  
Hai-feng Song ◽  
Cheng Luo ◽  
Lei Liang ◽  
Qian Zhang

Abstract The authors have requested that this preprint be removed from Research Square.


Oncogene ◽  
2019 ◽  
Vol 38 (49) ◽  
pp. 7367-7383 ◽  
Author(s):  
Heng-Jia Liu ◽  
Hilaire C. Lam ◽  
Christian V. Baglini ◽  
Julie Nijmeh ◽  
Alischer A. Cottrill ◽  
...  

2007 ◽  
Vol 21 (10) ◽  
pp. 2416-2426 ◽  
Author(s):  
Maxy De los Santos ◽  
Alberto Zambrano ◽  
Aurora Sánchez-Pacheco ◽  
Ana Aranda

Abstract The retinoic acid receptor β (RARβ) is a retinoic acid (RA)-inducible tumor suppressor, which plays an important role in the arrest of neuroblastoma cell growth. Using human neuroblastoma SH-SY5Y cells, we have examined the regulation of RARβ expression by histone deacetylase inhibitors (HDACi), considered to be promising agents in anticancer therapy. Our results show that HDACi cooperated with RA to increase RARβ mRNA levels and to activate the RARβ2 promoter in transient transfection assays. Chromatin immunoprecipitation assays showed that the basal RARβ2 promoter that contains the RA response element was refractory to acetylation by both HDACi and RA. In addition, HDACi caused a transient increase in acetylation of a downstream RARβ2 region, even though global histones remain hyperacetylated after a prolonged treatment with the inhibitors. RA potentiated this response and maintained acetylation for a longer period. Despite the cooperation of RA with HDACi to increase transcription of the RARβ gene, these inhibitors caused a paradoxical reduction of the cellular levels of the RARβ protein in cells treated with the retinoid. This reduction is secondary to a change in the protein half-life that is decreased by the HDACi due to increased ubiquitin-independent proteasomal degradation. These results show that HDACi regulate expression of the tumor suppressor gene RARβ by both transcriptional and posttranscriptional mechanisms and might then modulate sensitivity to the retinoid in neuroblastoma cells.


2007 ◽  
Vol 249 (2) ◽  
pp. 220-226 ◽  
Author(s):  
Qian Zhang ◽  
Jianming Ying ◽  
Kai Zhang ◽  
Hongyu Li ◽  
Ka Man Ng ◽  
...  

2006 ◽  
Vol 281 (29) ◽  
pp. 20474-20482 ◽  
Author(s):  
Annie L. Eisinger ◽  
Lincoln D. Nadauld ◽  
Dawne N. Shelton ◽  
Peter W. Peterson ◽  
Reid A. Phelps ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document